Fate Therapeutics Inc (FATE)

Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell

$0.75

Buy

$0.78

arrow-up$0.0729 (+10.72%)

Prices updated at 04 Apr 2025, 23:27 EDT
| Prices minimum 15 mins delay
|
Prices in USD
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of programmed cellular immunotherapies for cancer and immune disorders.
NASDAQ
arrow-down-5.82%
NASDAQ
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.

Profit margins

Created with Highcharts 7.2.2Gross margin (%)Operating margin (%)EBITDA margin (%)Net margin (%)20202021202220232024-2000-1500-1000-5000

Valuation

Created with Highcharts 7.2.2Price earningsPrice / SalesPrice / Cash flow202120222023202420250255075100125

Profit margins data table

Year
chevron-l-regular
chevron-r-regular
Gross margin (%)
2024-
2023-
2022-
2021-
2020-
2019-
2018-
2017-
2016-

Valuation data table

Year
chevron-l-regular
chevron-r-regular
Price / Sales
20256.28
202413.36
20233.45
202214.10
202199.15
2020393.94
2019134.26
2018159.20
201760.07
201616.70
201558.27
Price/Forward earnings (YTD)
-0.46

Returns

Created with Highcharts 7.2.2Return on assets (%)Return on equity (%)Return on invested capital (%)20202021202220232024-60-40-200

Debt profile

Created with Highcharts 7.2.2Financial leverage2020202120222023202400.511.52

Returns data table

Year
chevron-l-regular
chevron-r-regular
Return on assets (%)
2024-39.34
2023-26.56
2022-34.63
2021-27.48
2020-37.50
2019-38.09
2018-41.84
2017-42.88
2016-41.06

Debt profile data table

YearFinancial leverage
20241.38
20231.37
20221.46
20211.36
20201.62
20191.24
20181.33
20171.36
20161.30
The figures shown in the Profit Margins table EBITDA column are quoted in the currency of the stock selected.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.